Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model

Breast Cancer Res Treat. 2009 Oct;117(3):517-24. doi: 10.1007/s10549-008-0169-0. Epub 2008 Sep 9.

Abstract

The ACI rat is a unique model of human breast cancer in that mammary cancers are induced by estrogen without carcinogens, irradiation, xenografts or transgenic manipulations. We sought to characterize mammary cancers in a congenic variant of the ACI rat, the ACI.COP-Ept2. All rats with estradiol implants developed mammary cancers in 5-7 months. Rats bearing estradiol-induced mammary cancers were treated with tamoxifen for three weeks. Tamoxifen reduced tumor mass, measured by magnetic resonance imaging, by 89%. Tumors expressed estrogen receptors (ER), progesterone receptor (PR), and Erbb2. ERalpha and PR were overexpressed in tumor compared to adjacent non-tumor mammary gland. Thus, this model is highly relevant to hormone responsive human breast cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Congenic
  • Disease Models, Animal
  • Estradiol / toxicity*
  • Estrogens / toxicity*
  • Female
  • Humans
  • Immunohistochemistry
  • Mammary Neoplasms, Animal / chemically induced
  • Mammary Neoplasms, Animal / drug therapy*
  • Mammary Neoplasms, Animal / metabolism
  • Rats
  • Receptor, ErbB-2 / biosynthesis
  • Receptors, Estrogen / biosynthesis
  • Receptors, Progesterone / biosynthesis
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / therapeutic use*

Substances

  • Estrogens
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Estradiol
  • ERBB2 protein, human
  • Receptor, ErbB-2